Project Description:
A Randomised, Double-Blind, Placebo-Controlled Parallel-Group Trial to Confirm the Efficacy after 12 Weeks and the Safety of Tiotropium 5 micrograms Administered Once Daily Via the Respimat Device in Patients with Cystic Fibrosis.
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Professionals and Para-Professionals
Unserved or Under-served Populations:
Racial or Ethnic Minorities, Disadvantaged Circumstances, Limited English, Geographic Areas
Primary Target Audience Geographic Descriptor:
National
COVID-19 Related Data:
N/A